Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O96006

UPID:
ZBED1_HUMAN

ALTERNATIVE NAMES:
DNA replication-related element-binding factor; Putative Ac-like transposable element; Zinc finger BED domain-containing protein 1; dREF homolog

ALTERNATIVE UPACC:
O96006; Q96BY4

BACKGROUND:
The E3 SUMO-protein ligase ZBED1, with alternative names such as Zinc finger BED domain-containing protein 1, is integral to transcription regulation and cell proliferation. It achieves this by sumoylating CHD3/Mi2-alpha, thus lifting transcription repression and promoting RNA polymerase II activity on gene promoters. This mechanism is crucial for the transcription of various proteins, including ribosomal proteins, which are essential for cell growth. ZBED1's ability to bind to adenovirus gene promoters also highlights its role in microbial infection responses.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of E3 SUMO-protein ligase ZBED1 unveils potential avenues for developing novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.